Wall Street expects a year-over-year increase in earnings on higher revenues when 10x Genomics (TXG) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if these key numbers are better than expec ...

● Torex Gold Provides Q2 2024 Update on Media Luna Project (All amounts expressed in U.S. dollars unless otherwise stated) "Development of Media Luna continues to track to schedule, with first production of copper concentrate anticipated by year end and commercial production expected in Q1 2025. As at the end of June, Media Luna was 78% complete across engineering, procurement, underground development/construction, and surface construction, compared to 69% at the end of March. "With completion of Media Luna ...

Why TXG Could Witness a Solid Upside Here's What You Should Know About Analysts' Price Targets The average comprises 16 short-term price targets ranging from a low of $16 to a high of $55, with a standard deviation of $12.57. While the lowest estimate indicates a decline of 20% from the current price level, the most optimistic estimate points to a 175% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard d ...

Company Overview - 10x Genomics experienced a significant stock price increase of 8.2%, closing at $16.99, driven by investor optimism following the announcement of its Xenium In Situ platform's use in a study published in the Journal of Dental Research [1][4] - The company is set to report its second-quarter 2024 financial results on August 8, with revenue and earnings expected to grow by 3.1% and 13.2% respectively [1][5] Financial Performance Expectations - The consensus estimate for 10x Genomics' upcoming quarterly loss is projected at $0.46 per share, reflecting a year-over-year change of +13.2% [5] - Revenue expectations for the quarter stand at $151.42 million, which is an increase of 3.1% compared to the same quarter last year [5] Market Position and Trends - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting stability in earnings expectations [6] - 10x Genomics is part of the Zacks Medical Info Systems industry, which includes other companies like Azenta (AZTA), which saw a 4.5% increase in its stock price recently [7]

Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event. Disclosure Information SOURCE 10x Genomics, Inc. PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thur ...

Torex Gold Reports Positive Results from the 2024 ELG Underground Drilling Program June 27, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces assay results from the Company's ongoing drilling program at El Limón Guajes ("ELG") Underground. The results to date support Torex's target of extending the mine life of ELG Underground beyond 2028 by identifying new zones of higher-grade ...

Core Insights - 10x Genomics' Xenium In Situ platform was utilized in a study published in the Journal of Dental Research, providing new insights into the cellular mechanisms involved in secondary palate formation [1][2] - The study highlights the role of the Pax9 protein as a transcription factor in Wnt signaling, which is crucial for embryonic development [2][3] Company Overview - 10x Genomics is a leader in single cell and spatial biology, offering integrated solutions that include instruments, consumables, and software to enhance biological research [8][9] - The company's products are instrumental in advancing research across various fields, including oncology, immunology, and neuroscience, contributing to significant breakthroughs in understanding health and disease [9] Research Findings - The study revealed that the Xenium platform allowed for higher spatial resolution in gene expression analysis, enhancing the understanding of signaling pathways in palate development [3][4] - Researchers found significant differences in spatial gene expression between wild-type and Pax9-deficient mice, indicating Pax9's role in progenitor cell differentiation and maturation [6][7] - The analysis suggested that disrupted Wnt signaling due to loss of Pax9 expression affects proper bone formation, which could lead to potential therapeutic strategies for cleft palate anomalies [4][6]

New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput Key features of the new high-plex Xenium Prime 5K assay include: About 10x Genomics This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisi ...

Core Viewpoint - Torex Gold Resources Inc. has outlined a multi-year exploration strategy for its Morelos Property, aiming to enhance mineral resources, achieve new discoveries, and extend the mine life beyond 2033 to ensure stable production and cash flow [2][3][6]. Exploration Strategy Overview - The Morelos Property spans 29,000 hectares within the Guerrero Gold Belt, featuring the ELG Mine Complex and Media Luna Project. The company has invested an average of $31 million annually in drilling and resource expansion since 2021, with a budget of $30 million for 2024 [6][7]. - The exploration strategy aims to maintain over 450,000 gold equivalent ounces (oz AuEq) of annual production beyond 2027 and to make at least one new discovery in the coming years [7][8]. Target Areas - The exploration strategy focuses on three main areas: 1. Extending the mine life of ELG Underground and Media Luna through infill and near-mine step-out drilling [7]. 2. Expanding resources within the Media Luna Cluster, including Media Luna, EPO, Media Luna West, Media Luna East, and Todos Santos [7]. 3. Advancing new exploration targets such as El Naranjo, Atzcala, Esperanza, Querenque, Tecate, El Olvido, and Victoria [7][8]. Geological Understanding - The company has identified three dominant styles of mineralization at Morelos: skarn, intermediate sulphidation (IS), and carbonate replacement deposits (CRD). This evolving understanding supports the potential for new discoveries [8][25]. Exploration Pipeline - The exploration pipeline includes various stages from target selection to resource delineation. The company aims to advance each target based on economic potential and strategic objectives [9][10]. - The 2023 drilling program successfully expanded Measured & Indicated Resources by 570 thousand oz AuEq, leading to an increase in Proven & Probable Reserves by 280 thousand oz AuEq, extending the mine life of ELG Underground by two years through 2028 [11][12]. Regional Exploration - A budget of $3 million is allocated for regional exploration in 2024, with plans for 3,000 meters of intermediate drill testing at El Naranjo to delineate geological features [21][22]. - The company is also exploring potential extensions to structural corridors on the north side of the Balsas River, similar to those at the ELG deposit [22]. Longer-Dated Targets - Other promising targets include Querenque, Tecate, Esperanza, El Olvido, and Victoria, which will be evaluated and advanced as appropriate in the exploration pipeline over the coming years [24][48].

The Xenium Prime 5K assay, optimized for human and mouse species, is now available for preorder and is expected to ship next month. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resol ...